Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 53, Issue 3, 2009, Pages 505-508

  Keshelava, Nino ^a   Houghton, Peter J ^b   Morton, Christopher L ^b   Lock, Richard B ^c   Carol, Hernan ^c   Keir, Stephen T ^d   Maris, John M ^e   Reynolds, C Patrick ^f   Gorlick, Richard ^g   Kolb, E Anders ^h   Wu, Jianrong ^b   Smith, Malcolm A ⁱ  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^h NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Preclinical testing; Vorinostat

Indexed keywords

VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG SCREENING; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, INBRED BALB C; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651205908     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21988     Document Type: Article

References (20)

1. Glaser KB. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol 2007;74:659-671.
2. Richon VM. Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006;95:5.
3. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-10019.
4. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 2001;98:2865-2868.
5. Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma. J Clin Oncol 2007;25: Abstr #3500.
6. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
7. Duvic M, Vu J. Vorinostat: A neworal histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-1120. (Pubitemid 47074165)
8. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115. (Pubitemid 47218059)
9. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007;13:2318-2322. (Pubitemid 46698579)
10. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931. (Pubitemid 46218695)
11. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588. (Pubitemid 37169221)
12. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:37-45. (Pubitemid 350234263)
13. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of Nmyc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-406.
14. Reynolds CP, Matthay KK, Villablanca JG, et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192.
15. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000;35:577-581.
16. Kutko MC, Glick RD, Butler LM, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003;9:5749-5755.
17. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940. (Pubitemid 350022448)
18. Keshelava N, Davicioni E, Wan Z, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007;99:1107-1119. (Pubitemid 47241395)
19. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003;9:1033-1038.
20. Gumireddy K, Sutton LN, Phillips PC, et al. All-trans-retinoic acid-induced apoptosis in human medulloblastoma: Activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Clin Cancer Res 2003;9:4052-4059. (Pubitemid 37204020)